Disruption of latent HIV in vivo during the clearance of actinic keratosis by ingenol mebutate.
暂无分享,去创建一个
G. Jiang | J. Wong | D. Hartigan-O’Connor | S. Dandekar | M. Shimoda | J. Estes | E. Maverakis | C. Deleage | G. Méndez-Lagares | M. Cheng | S. Yukl | Maher M. Elsheikh | G. Thompson
[1] H. Hatano,et al. Gut and blood differ in constitutive blocks to HIV transcription, suggesting tissue-specific differences in the mechanisms that govern HIV latency , 2018, PLoS pathogens.
[2] E. Stockfleth,et al. Nonmelanoma skin cancer – from actinic keratosis to cutaneous squamous cell carcinoma , 2018, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.
[3] J. Wong,et al. HIV latency in isolated patient CD4+ T cells may be due to blocks in HIV transcriptional elongation, completion, and splicing , 2018, Science Translational Medicine.
[4] D. Margolis,et al. HIV latency is reversed by ACSS2-driven histone crotonylation , 2018, The Journal of clinical investigation.
[5] I. Sadowski,et al. Compounds producing an effective combinatorial regimen for disruption of HIV‐1 latency , 2017, EMBO molecular medicine.
[6] T. Chun,et al. In vivo activation of latent HIV with a synthetic bryostatin analog effects both latent cell "kick" and "kill" in strategy for virus eradication , 2017, PLoS pathogens.
[7] C. Tepper,et al. Oncolytic Reactivation of KSHV as a Therapeutic Approach for Primary Effusion Lymphoma , 2017, Molecular Cancer Therapeutics.
[8] D. Hazuda,et al. HDAC inhibition induces HIV-1 protein and enables immune-based clearance following latency reversal. , 2017, JCI insight.
[9] J. Blankson,et al. The effect of Ingenol-B on the suppressive capacity of elite suppressor HIV-specific CD8+ T cells , 2017, PloS one.
[10] A. Rice,et al. Assays for precise quantification of total (including short) and elongated HIV-1 transcripts. , 2017, Journal of Virological Methods.
[11] M. Tremblay,et al. HIV-1 Latency-Reversing Agents Prostratin and Bryostatin-1 Induce Blood–Brain Barrier Disruption/Inflammation and Modulate Leukocyte Adhesion/Transmigration , 2017, The Journal of Immunology.
[12] Anna Kula,et al. Reactivation capacity by latency-reversing agents ex vivo correlates with the size of the HIV-1 reservoir , 2017, AIDS.
[13] R. Siliciano,et al. Reactivation of simian immunodeficiency virus reservoirs in the brain of virally suppressed macaques , 2016, AIDS.
[14] B. Walker,et al. Single-Cell Characterization of Viral Translation-Competent Reservoirs in HIV-Infected Individuals. , 2016, Cell host & microbe.
[15] H. Haenssle,et al. Tumor-Preferential Induction of Immune Responses and Epidermal Cell Death in Actinic Keratoses by Ingenol Mebutate , 2016, PloS one.
[16] B. Turkbey,et al. Imaging lymphoid tissues in nonhuman primates to understand SIV pathogenesis and persistence. , 2016, Current opinion in virology.
[17] J. Lifson,et al. Defining HIV and SIV Reservoirs in Lymphoid Tissues , 2016, Pathogens & immunity.
[18] Coral Barbas,et al. Bryostatin-1 for latent virus reactivation in HIV-infected patients on antiretroviral therapy , 2016, AIDS.
[19] Yuyang Tang,et al. Synergistic Reactivation of Latent HIV Expression by Ingenol-3-Angelate, PEP005, Targeted NF-kB Signaling in Combination with JQ1 Induced p-TEFb Activation , 2015, PLoS pathogens.
[20] C. Cook,et al. The treatment of carcinoma in situ and squamous cell carcinoma of the conjunctiva with fractionated strontium-90 radiation in a population with a high prevalence of HIV , 2015, British Journal of Ophthalmology.
[21] G. Jiang,et al. Targeting NF-κB signaling with protein kinase C agonists as an emerging strategy for combating HIV latency. , 2015, AIDS research and human retroviruses.
[22] A. Tanuri,et al. Reactivation of HIV latency by a newly modified Ingenol derivative via protein kinase C&dgr;–NF-&kgr;B signaling , 2014, AIDS.
[23] J. Wong,et al. Advantages of using the QIAshredder instead of restriction digestion to prepare DNA for droplet digital PCR. , 2014, BioTechniques.
[24] Neil Swanson,et al. Ingenol mebutate gel for actinic keratosis. , 2012, The New England journal of medicine.
[25] Mahendra Kumar,et al. Human immunodeficiency virus type 1 RNA Levels in different regions of human brain: Quantification using real-time reverse transcriptase-polymerase chain reaction , 2011, Journal of NeuroVirology.
[26] E. Maverakis,et al. Light, including ultraviolet. , 2010, Journal of autoimmunity.
[27] S. Ogbourne,et al. PEP005 (ingenol mebutate) gel, a novel agent for the treatment of actinic keratosis: Results of a randomized, double‐blind, vehicle‐controlled, multicentre, phase IIa study , 2009, The Australasian journal of dermatology.
[28] Jean Kanitakis,et al. Detection of human immunodeficiency virus-DNA and RNA in the skin of HIV-infected patients using the polymerase chain reaction. , 1991, The Journal of investigative dermatology.